News

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed his experience with and reaction to the approval of Casgevy.

The trial has completed enrollment and all 14 patients have demonstrated islet cell engraftment and endogenous insulin production.

The clearance continues a recent trend of IND clearances for CAR-T therapies in autoimmune disease.

The chief hematology/oncology fellow at University of Chicago discussed real-world experience data and new analyses of patients with B-cell acute lymphoblastic leukemia treated with brexu-cel.

Alexis Thompson, MD, MPH, the chief of hematology at Children’s Hospital of Philadelphia, discussed an analysis of follow-up data for bluebird bio’s beti-cel she presented at ASH’s 2023 conference.

No unifying characteristics were found in a small subset of 6 patients from the BENEGENE-2 trial.

The clinical associate professor at Stanford Medicine discussed new research on patients who have received HCT or gene therapy for SCD.

Review top news and interview highlights from the week ending January 5, 2024.

The internal medicine resident physician at University of Kansas Medical Center discussed research conducted into gender authorship rates of 13 pivotal trials published between 2017 and 2022.

The FDA and EMA have accepted marketing authorization applications and decisions are pending.

Senti Bio anticipates the launch of a multicenter clinical trial in hematological malignancies this year, with the first patient expected to receive the therapy within 2024’s second quarter.

The AAV-SLB101 capsid used in SGT-003 may yield increased transgene expression and improved safety compared with first-generation AAV gene therapies.

The cofounder, executive vice president, and chief medical officer, CLL Society, discussed updates in CLL research in the field in general and presented at the ASH 2023 meeting.

The approval of exa-cel, the first gene editing therapy, may herald a new era in developing gene editing strategies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief of hematology at Children’s Hospital of Philadelphia discussed dual approval of the 2 gene therapies that coincided with ASH’s 2023 conference.

Ocugen and the FDA have agreed on trial design aspects including end point, patient enrollment strategy, and study duration.

CGTLive spoke with Donald Wood, PhD, president and CEO of the MDA while looking ahead to its March conference.

The associate professor at Peter MacCallum Cancer Centre discussed further research and questions that need to be investigated with the cell therapy.

ONCT-808 targets ROR1 and is currently being evaluated for the treatment of r/r aggressive B-cell lymphoma.

ACGT is advancing cell and gene therapy research for pancreatic tumors and other types of cancer.

These, among many others, are some of the key clinical trials of gene, cell, and regenerative therapies that the CGTLive staff will be following throughout 2024.

Take a look at the stories that stood out as pillars of progress and success in endocrinology gene and cell therapy development in 2023.

This year we reached out to numerous experts outside the context of the conference cycle to seek their insight on company announcements, pipeline therapies, and disease awareness days.

Take a look back at the 2023 conference, hosted by the University of Calgary and McMaster University, and held in Banff, Alberta, Canada.

Take a look at our most-read features from 2023 that explored the biggest current topics and concerns with gene and cell therapy development across treatment fields.

Take a look at the stories that stood out as pillars of progress and success from all of CGTLive's coverage of major 2023 medical society meetings and conferences.

Take a look at the interviews that stood out as pillars of progress and success from all of CGTLive's coverage of major 2023 medical society meetings and conferences.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Take a look at the stories that stood out as pillars of progress and success in cardiology gene and cell therapy development in 2023.